Podcast Sponsored podcast

Changing bioscience research using CRISPR-edited cell models

This podcast is brought to you by the Science/AAAS Custom Publishing Office

Changing bioscience research using CRISPR-edited cell models

01 August 2019

2:00 p.m. ET

Listen Now!


Welcome to an exciting and engaging new podcast series from Science Custom Solutions! In this three-part series, we’ll be talking to prominent bioscientists across a range of research fields about how they’re applying and adapting the latest technologies—in particular the most recent advances in CRISPR-based gene editing—to their area of study.

The first of the three interviewees is Dr. Robin Ketteler from the Laboratory for Molecular Cell Biology Group Leader and High Content Biology Leader at University College London in the United Kingdom.  Robin is an expert in cell signaling and autophagy.  Next is Dr. Stephen Jackson, professor in the Department of Biochemistry at the Wellcome Trust/Cancer Research UK Gurdon Institute at the University of Cambridge. He studies DNA damage and repair. Our final guest is Dr. Mathias Uhlén from KTH Royal Institute of Technology. His broad focus is protein science and antibody engineering, but this time Mathias will be talking to us specifically about antibody validation.

Future eposides will be released at 2-week intervals.

Our thanks to Horizon Discovery for their kind sponsorship of this webinar series. From research to therapy, Horizon Discovery drives the application of gene editing and gene modulation. Innovative tools and services enable scientists to gain a greater understanding of the genetic drivers behind disease, develop and validate diagnostic workflows, and deliver new therapies for precision medicine.

Speaker bios

Robin Ketteler, Ph.D.

MRC Laboratory for Molecular Cell Biology
University College London
London, UK

Dr. Ketteler is a group leader at University College London and manages the Medical Research Council Laboratory for Molecular Cell Biology High-Content Screening Platform. He studied biochemistry at the Free University of Berlin and completed his Ph.D. in 2002 at the Max-Planck Institute of Immunobiology in Freiburg, Germany. He undertook his postdoctoral studies at Massachusetts General Hospital in Boston and joined University College London in 2009. His current research focuses on the regulation of autophagy by posttranslational modifications, utilizing the power of siRNA screening, CRISPR/Cas9 genome editing, and high-content imaging.

Stephen P. Jackson, Ph.D., FRS, FMedSci

The Gurdon Institute and Department of Biology
University of Cambridge
Cambridge, UK

Dr. Jackson is University of Cambridge Professor of Biology, and head of Cancer Research UK Laboratories at the Gurdon Institute. His research has identified key principles by which cells respond to and repair DNA damage, and has helped define how cellular dysfunction leads to cancer and other age-related diseases. His academic laboratory is currently further defining mechanisms of DNA repair and associated processes, with a view to delivering new biological insights and identifying therapeutic opportunities for cancer and other diseases. He is a fellow of the Royal Society and has received many prizes, including the 2015 Gagna A. and Ch. Van Heck Prize for Medicine, the 2016 King Faisal International Prize for Science, the 2016 Dr. A.H. Heineken Prize for Medicine, and the 2019 Fondation ARC Léopold Griffuel Award for Translational and Clinical Research. To translate his academic work into patient benefit, he founded several commercial entities, including the drug-discovery company KuDOS Pharmaceuticals Ltd., where he served as part-time chief scientific officer, and Mission Therapeutics Ltd., where until recently he was part-time CSO. His research also underpinned the foundation of Carrick Therapeutics Ltd., which he now serves as a scientific advisor. Dr. Jackson is a Science Partner of Ahren Innovation Capital and serves as part-time chief executive officer for Adrestia Therapeutics Ltd., a company he cofounded in 2018. 

Mathias Uhlén, Ph.D.

KTH Royal Institute of Technology
Stockholm, Sweden

Dr. Uhlén received his Ph.D. in chemistry at the Royal Institute of Technology (KTH) in Stockholm, Sweden. After postdoctoral training at the European Molecular Biology Laboratory in Heidelberg, Germany, he became professor of microbiology at KTH in 1988. Dr. Uhlén founded the Science for Life Laboratory in Stockholm, Sweden, where he served as director from 2010 to 2015, and has authored more than 750 publications in bioscience with a focus on the development and use of affinity reagents in biotechnology and biomedicine. He has founded 10 companies and has more than 70 patents and patent applications to his name. He is a member of the Royal Swedish Academy of Engineering Sciences, the Royal Swedish Academy of Sciences, the European Molecular Biology Organization, and the National Academy of Engineering, and is president of the European Federation of Biotechnology. He was the first to describe the use of affinity tags for purification of proteins and the use of biotin-streptavidin for DNA handling, methods now widely used in bioscience. He is leading the international effort to create the Human Protein Atlas with the aim of systematically mapping the entire human proteome. Dr. Uhlén has received numerous awards, including the AkzoNobel Science Award, the Seraphim Medal from His Majesty the King of Sweden, the HUPO Distinguished Achievement in Proteomic Sciences Award, and the ABRF Award for Outstanding Contributions to Biomolecular Technologies.

Sponsored by